Zdrowie i gospodarka · 29/04/2022
FDA Clears Cupric Sulfate Injection for Approval, Allows for Abbreviated New Drug Applications
The FDA has determined that Cupric Sulfate Injection, equivalent to 0.4 milligram copper/milliliter, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications for this product.
Source: Federal Register — Food and Drug AdministrationOpen original release →